One of the crucial aspects of screening antisense oligonucleotides destined for therapeutic application is confidence that the antisense oligomer is delivered efficiently into cultured cells. Efficient delivery is particularly vital for antisense phosphorodiamidate morpholino oligomers, which have a neutral backbone, and are known to show poor gymnotic uptake. Here, we report several methods to deliver these oligomers into cultured cells. Although 4D-NucleofectorTM or Neon. electroporation systems provide efficient delivery and use lower amounts of phosphorodiamidate morpholino oligomer, both systems are costly. We show that some readily available transfection reagents can be used to deliver phosphorodiamidate morpholino oligomers as effici...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
Antisense oligonucleotide therapy for Duchenne muscular dystrophy has shown great potential in precl...
The mdx mouse model of muscular dystrophy arose due to a nonsense mutation in exon 23 of the dystrop...
Recent advances in drug development have seen numerous successful clinical translations using synthe...
Phosphorodiamidate morpholino oligomers (PMO) are short single-stranded DNA analogs that are built u...
Phosphorodiamidate morpholino oligomers (PMOs) are oligonucleotide analogs that can be used for ther...
Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful the...
An efficient method for the delivery of uncharged polyA-tailed phosphorodiamidate morpholino sequenc...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The published arti...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
Graduation date: 2014Peptide-phosphorodiamidate morpholino oligomers (PPMOs) are synthetic\ud DNA mi...
Mingxing Wang, Bo Wu, Jason D Tucker, Peijuan Lu, Qilong Lu Department of Neurology, McColl-Lockwoo...
Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and m...
<p>Phosphorodiamidate morpholino oligonucleotides (PMOs) are a class of antisense oligonucleotides u...
Antisense oligonucleotide therapy is one of the most promising strategies for treatment of myotonic ...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
Antisense oligonucleotide therapy for Duchenne muscular dystrophy has shown great potential in precl...
The mdx mouse model of muscular dystrophy arose due to a nonsense mutation in exon 23 of the dystrop...
Recent advances in drug development have seen numerous successful clinical translations using synthe...
Phosphorodiamidate morpholino oligomers (PMO) are short single-stranded DNA analogs that are built u...
Phosphorodiamidate morpholino oligomers (PMOs) are oligonucleotide analogs that can be used for ther...
Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful the...
An efficient method for the delivery of uncharged polyA-tailed phosphorodiamidate morpholino sequenc...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The published arti...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
Graduation date: 2014Peptide-phosphorodiamidate morpholino oligomers (PPMOs) are synthetic\ud DNA mi...
Mingxing Wang, Bo Wu, Jason D Tucker, Peijuan Lu, Qilong Lu Department of Neurology, McColl-Lockwoo...
Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and m...
<p>Phosphorodiamidate morpholino oligonucleotides (PMOs) are a class of antisense oligonucleotides u...
Antisense oligonucleotide therapy is one of the most promising strategies for treatment of myotonic ...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
Antisense oligonucleotide therapy for Duchenne muscular dystrophy has shown great potential in precl...
The mdx mouse model of muscular dystrophy arose due to a nonsense mutation in exon 23 of the dystrop...